Literature DB >> 2173804

The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia.

A Tefferi1, G D Bren, K V Wagner, D J Schaid, R C Ash, S N Thibodeau.   

Abstract

Chronic granulocytic leukemia (CGL) is associated with a reciprocal translocation between chromosomes 9 and 22. The breakpoint sites on chromosome 22 are clustered in a limited region known as the major breakpoint cluster region (Mbcr). This region is approximately 5.8 Kb long and can be arbitrarily subdivided into five zones (1 through 5 from the 5' towards the 3' end) as defined by the particular sites of three restriction endonucleases. Using Southern blot analysis with two DNA probes, one spanning both the 5' and 3' regions of the Mbcr while the other only the 3' region, we mapped the precise location of the chromosomal breakpoints within the Mbcr in 62 patients with CGL and examined possible clinical correlations. There were 39 patients with 5' breakpoints (zones 1-3) and 23 patients with 3' breakpoints (zones 4 and 5). We found no correlation between the clinical phase of the disease at last followup and breakpoint distributions. The distributions of chronic phase duration (CPD) and survival were similar between patients with 5' breakpoints (median CPD = 4.0 years) and those with 3' breakpoints (median CPD = 5.2 years). Presenting clinical features and the rates of lymphoblastic transformation were also similar among the subgroups. Our data suggest that the precise location of the breakpoint within the Mbcr in CGL may not have clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173804

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Authors:  Benjamin Hanfstein; Michael Lauseker; Rüdiger Hehlmann; Susanne Saussele; Philipp Erben; Christian Dietz; Alice Fabarius; Ulrike Proetel; Susanne Schnittger; Claudia Haferlach; Stefan W Krause; Jörg Schubert; Hermann Einsele; Mathias Hänel; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Markus Pfirrmann; Joerg Hasford; Wolf-Karsten Hofmann; Andreas Hochhaus; Martin C Müller
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

2.  Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Authors:  Preetesh Jain; Hagop Kantarjian; Keyur P Patel; Graciela Nogueras Gonzalez; Rajyalakshmi Luthra; Rashmi Kanagal Shamanna; Koji Sasaki; Elias Jabbour; Carlos Guillermo Romo; Tapan M Kadia; Naveen Pemmaraju; Naval Daver; Gautam Borthakur; Zeev Estrov; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal:  Blood       Date:  2016-01-04       Impact factor: 22.113

3.  Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Andrea Davies; Katy Knight; Sarah J Watmough; Lihui Wang; Richard E Clark
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

4.  Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project.

Authors:  Mohammad A J Abdulla; Prem Chandra; Susanna El Akiki; Mahmood B Aldapt; Sundus Sardar; Ammar Chapra; Abdulqadir J Nashwan; Claudio Sorio; Luisa Tomasello; Christian Boni; Mohamed A Yassin
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

Review 5.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

6.  Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib.zzm321990A First of Its Kind Study on CML Patients of Kashmir

Authors:  Niyaz A Azad; Zafar A Shah; Arshad A Pandith; Mosin S Khan; Roohi Rasool; Javed Rasool; Shiekh A Aziz
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25

7.  Protection from β-cell apoptosis by inhibition of TGF-β/Smad3 signaling.

Authors:  Ji-Hyeon Lee; Jose Manuel Mellado-Gil; Young Jae Bahn; Sushrut M Pathy; Ying E Zhang; Sushil G Rane
Journal:  Cell Death Dis       Date:  2020-03-13       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.